Avalo Therapeutics Buys Out $15M Milestone for $7.375M, Saving $7.6M
AVTX has more than doubled off its 52-week low of $3.39.
Summary
Avalo Therapeutics has entered into an agreement to buy out a previously disclosed $15 million contingent milestone payment related to its March 2024 acquisition of AlmataBio, Inc. The company paid $2.25 million for an option, exercisable within 90 days, to pay an additional $5.125 million in cash or stock, or a combination thereof. This effectively reduces a $15 million future obligation to $7.375 million, representing a net saving of $7.625 million. This financial maneuver is a positive development, reducing a significant future liability for a clinical-stage biotech company that has reported widened net losses and increased cash burn, as noted in its recent 10-K. The option to pay in shares also aligns with the company's existing $750 million universal shelf registration.
At the time of this announcement, AVTX was trading at $14.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $385.2M. The 52-week trading range was $3.39 to $20.72. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.